-
2
-
-
0037406061
-
Class II histone deacetylases: Versatile regulators
-
Verdin E, Dequiedt F, Kasler HG. Class II histone deacetylases: versatile regulators. Trends Genet. 2003;19:286-93.
-
(2003)
Trends Genet
, vol.19
, pp. 286-293
-
-
Verdin, E.1
Dequiedt, F.2
Kasler, H.G.3
-
3
-
-
30344477367
-
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
-
Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer. 2006;6:38-51.
-
(2006)
Nat Rev Cancer
, vol.6
, pp. 38-51
-
-
Minucci, S.1
Pelicci, P.G.2
-
4
-
-
77249087051
-
Chemical phylogenetics of histone deacetylases
-
Bradner JE, West N, Grachan ML, Greenberg EF, Haggarty SJ, Warnow T, Mazitschek R. Chemical phylogenetics of histone deacetylases. Nat Chem Biol. 2010;6:238-43.
-
(2010)
Nat Chem Biol
, vol.6
, pp. 238-243
-
-
Bradner, J.E.1
West, N.2
Grachan, M.L.3
Greenberg, E.F.4
Haggarty, S.J.5
Warnow, T.6
Mazitschek, R.7
-
5
-
-
9144220841
-
Transcriptional signature of histone deacetylase inhibition in multiple myeloma: Biological and clinical implications
-
Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Hideshima T, Akiyama M, Chauhan D, Munshi N, Gu X, Bailey C, Joseph M, Libermann TA, Richon VM, Marks PA, Anderson KC. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci USA. 2004;101:540-5.
-
(2004)
Proc Natl Acad Sci USA
, vol.101
, pp. 540-545
-
-
Mitsiades, C.S.1
Mitsiades, N.S.2
McMullan, C.J.3
Poulaki, V.4
Shringarpure, R.5
Hideshima, T.6
Akiyama, M.7
Chauhan, D.8
Munshi, N.9
Gu, X.10
Bailey, C.11
Joseph, M.12
Libermann, T.A.13
Richon, V.M.14
Marks, P.A.15
Anderson, K.C.16
-
6
-
-
10744229917
-
N-hydroxy-3- phenyl-2-propenamides as novel inhibitors of human histone deacetylase with in vivo antitumor activity: Discovery of (2e)-nhydroxy- 3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ETHYL]amino]- methyl]phenyl]-2- propenamide (NVP-LAQ824)
-
Remiszewski SW, Sambucetti LC, Bair KW, Bontempo J, Cesarz D, Chandramouli N, Chen R, Cheung M, Cornell-Kennon S, Dean K, Diamantidis G, France D, Green MA, Howell KL, Kashi R, Kwon P, Lassota P, Martin MS, Mou Y, Perez LB, Sharma S, Smith T, Sorensen E, Taplin F, Trogani N, Versace R, Walker H, Weltchek-Engler S, Wood A, Wu A, Atadja P. N-Hydroxy-3- phenyl-2-propenamides as novel inhibitors of human histone deacetylase with in vivo antitumor activity: discovery of (2E)-Nhydroxy- 3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl) ethyl]amino]- methyl]phenyl]-2-propenamide (NVP-LAQ824). J Med Chem. 2003;46:4609-24.
-
(2003)
J Med Chem
, vol.46
, pp. 4609-4624
-
-
Remiszewski, S.W.1
Sambucetti, L.C.2
Bair, K.W.3
Bontempo, J.4
Cesarz, D.5
Chandramouli, N.6
Chen, R.7
Cheung, M.8
Cornell-Kennon, S.9
Dean, K.10
Diamantidis, G.11
France, D.12
Green, M.A.13
Howell, K.L.14
Kashi, R.15
Kwon, P.16
Lassota, P.17
Martin, M.S.18
Mou, Y.19
Perez, L.B.20
Sharma, S.21
Smith, T.22
Sorensen, E.23
Taplin, F.24
Trogani, N.25
Versace, R.26
Walker, H.27
Weltchek-Engler, S.28
Wood, A.29
Wu, A.30
Atadja, P.31
more..
-
7
-
-
9144225360
-
Selective growth inhibition of tumor cells by a novel histone deacetylase inhibitor, NVP-LAQ824
-
Atadja P, Gao L, Kwon P, Trogani N, Walker H, Hsu M, Yeleswarapu L, Chandramouli N, Perez L, Versace R, Wu A, Sambucetti L, Lassota P, Cohen D, Bair K, Wood A, Remiszewski S. Selective growth inhibition of tumor cells by a novel histone deacetylase inhibitor, NVP-LAQ824. Cancer Res. 2004;64: 689-95.
-
(2004)
Cancer Res
, vol.64
, pp. 689-695
-
-
Atadja, P.1
Gao, L.2
Kwon, P.3
Trogani, N.4
Walker, H.5
Hsu, M.6
Yeleswarapu, L.7
Chandramouli, N.8
Perez, L.9
Versace, R.10
Wu, A.11
Sambucetti, L.12
Lassota, P.13
Cohen, D.14
Bair, K.15
Wood, A.16
Remiszewski, S.17
-
8
-
-
0141593496
-
NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma
-
Catley L, Weisberg E, Tai YT, Atadja P, Remiszewski S, Hideshima T, Mitsiades N, Shringarpure R, LeBlanc R, Chauhan D, Munshi N, Schlossman R, Richardson P, Griffin J, Anderson KC. NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood. 2003;102: 2615-22.
-
(2003)
Blood
, vol.102
, pp. 2615-2622
-
-
Catley, L.1
Weisberg, E.2
Tai, Y.T.3
Atadja, P.4
Remiszewski, S.5
Hideshima, T.6
Mitsiades, N.7
Shringarpure, R.8
Leblanc, R.9
Chauhan, D.10
Munshi, N.11
Schlossman, R.12
Richardson, P.13
Griffin, J.14
Anderson, K.C.15
-
9
-
-
20844444898
-
Combination of the histone deacetylase inhibitor LBH589 and the HSP90 inhibitor 17-AAG is highly active against human CML-BC cells and aml cells with activating mutation of FLT-3
-
George P, Bali P, Annavarapu S, Scuto A, Fiskus W, Guo F, Sigua C, Sondarva G, Moscinski L, Atadja P, Bhalla K. Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood. 2005;105:1768-76.
-
(2005)
Blood
, vol.105
, pp. 1768-1776
-
-
George, P.1
Bali, P.2
Annavarapu, S.3
Scuto, A.4
Fiskus, W.5
Guo, F.6
Sigua, C.7
Sondarva, G.8
Moscinski, L.9
Atadja, P.10
Bhalla, K.11
-
10
-
-
33745888156
-
Combined effects of novel tyrosine kinase inhibitoramn107 and histone deacetylase inhibitor lbh589 against bcr-abl-expressing human leukemia cells
-
Fiskus W, Pranpat M, Bali P, Balasis M, Kumaraswamy S, Boyapalle S, Rocha K, Wu J, Giles F, Manley PW, Atadja P, Bhalla K. Combined effects of novel tyrosine kinase inhibitorAMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells. Blood. 2006;108:645-52.
-
(2006)
Blood
, vol.108
, pp. 645-652
-
-
Fiskus, W.1
Pranpat, M.2
Bali, P.3
Balasis, M.4
Kumaraswamy, S.5
Boyapalle, S.6
Rocha, K.7
Wu, J.8
Giles, F.9
Manley, P.W.10
Atadja, P.11
Bhalla, K.12
-
11
-
-
33845741562
-
Histone deacetylase (HDAC) inhibitor lbh589 increases duration of gamma-H2AX foci and confines hdac4 to the cytoplasm in irradiated non-small cell lung cancer
-
Geng L, Cuneo KC, Fu A, Tu T, Atadja PW, Hallahan DE. Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer. Cancer Res. 2006;66: 11298-304.
-
(2006)
Cancer Res
, vol.66
, pp. 11298-11304
-
-
Geng, L.1
Cuneo, K.C.2
Fu, A.3
Tu, T.4
Atadja, P.W.5
Hallahan, D.E.6
-
12
-
-
33947242973
-
Abrogation of MAPK and AKT signaling by AEE788 synergistically potentiates histone deacetylase inhibitor-induced apoptosis through reactive oxygen species generation
-
Yu C, Friday BB, Lai JP, McCollum A, Atadja P, Roberts LR, Adjei AA. Abrogation of MAPK and Akt signaling by AEE788 synergistically potentiates histone deacetylase inhibitor-induced apoptosis through reactive oxygen species generation. Clin Cancer Res. 2007;13:1140-8.
-
(2007)
Clin Cancer Res
, vol.13
, pp. 1140-1148
-
-
Yu, C.1
Friday, B.B.2
Lai, J.P.3
McCollum, A.4
Atadja, P.5
Roberts, L.R.6
Adjei, A.A.7
-
13
-
-
33751172982
-
Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells
-
Catley L, Weisberg E, Kiziltepe T, Tai YT, Hideshima T, Neri P, Tassone P, Atadja P, Chauhan D, Munshi NC, Anderson KC. Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood. 2006;108:3441-9.
-
(2006)
Blood
, vol.108
, pp. 3441-3449
-
-
Catley, L.1
Weisberg, E.2
Kiziltepe, T.3
Tai, Y.T.4
Hideshima, T.5
Neri, P.6
Tassone, P.7
Atadja, P.8
Chauhan, D.9
Munshi, N.C.10
Anderson, K.C.11
-
14
-
-
33745258655
-
The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance
-
Maiso P, Carvajal-Vergara X, Ocio EM, Lopez-Perez R, Mateo G, Gutierrez N, Atadja P, Pandiella A, San Miguel JF. The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance. Cancer Res. 2006;66: 5781-9.
-
(2006)
Cancer Res
, vol.66
, pp. 5781-5789
-
-
Maiso, P.1
Carvajal-Vergara, X.2
Ocio, E.M.3
Lopez-Perez, R.4
Mateo, G.5
Gutierrez, N.6
Atadja, P.7
Pandiella, A.8
San, M.J.F.9
-
15
-
-
1642453460
-
Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101
-
Plumb JA, Finn PW, Williams RJ, Bandara MJ, Romero MR, Watkins CJ, La Thangue NB, Brown R. Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol Cancer Ther. 2003;2:721-8.
-
(2003)
Mol Cancer Ther
, vol.2
, pp. 721-728
-
-
Plumb, J.A.1
Finn, P.W.2
Williams, R.J.3
Bandara, M.J.4
Romero, M.R.5
Watkins, C.J.6
La Thangue, N.B.7
Brown, R.8
-
16
-
-
31544464120
-
Targeting tumor angiogenesis with histone deacetylase inhibitors: The hydroxamic acid derivative LBH589
-
Qian DZ, Kato Y, Shabbeer S, Wei Y, Verheul HM, Salumbides B, Sanni T, Atadja P, Pili R. Targeting tumor angiogenesis with histone deacetylase inhibitors: The hydroxamic acid derivative LBH589. Clin Cancer Res. 2006;12:634-42.
-
(2006)
Clin Cancer Res
, vol.12
, pp. 634-642
-
-
Qian, D.Z.1
Kato, Y.2
Shabbeer, S.3
Wei, Y.4
Verheul, H.M.5
Salumbides, B.6
Sanni, T.7
Atadja, P.8
Pili, R.9
-
17
-
-
3142689788
-
The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells
-
Lucas DM, Davis ME, Parthun MR, Mone AP, Kitada S, Cunningham KD, Flax EL, Wickham J, Reed JC, Byrd JC, Grever MR. The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells. Leukemia. 2004;18:1207-14.
-
(2004)
Leukemia
, vol.18
, pp. 1207-1214
-
-
Lucas, D.M.1
Davis, M.E.2
Parthun, M.R.3
Mone, A.P.4
Kitada, S.5
Cunningham, K.D.6
Flax, E.L.7
Wickham, J.8
Reed, J.C.9
Byrd, J.C.10
Grever, M.R.11
-
18
-
-
23244432614
-
Antitumor effects of histone deacetylase inhibitor on ewing's family tumors
-
Sakimura R, Tanaka K, Nakatani F, Matsunobu T, Li X, Hanada M, Okada T, Nakamura T, Matsumoto Y, Iwamoto Y. Antitumor effects of histone deacetylase inhibitor on Ewing's family tumors. Int J Cancer. 2005;116:784-92.
-
(2005)
Int J Cancer
, vol.116
, pp. 784-792
-
-
Sakimura, R.1
Tanaka, K.2
Nakatani, F.3
Matsunobu, T.4
Li, X.5
Hanada, M.6
Okada, T.7
Nakamura, T.8
Matsumoto, Y.9
Iwamoto, Y.10
-
20
-
-
33750463070
-
Cytotoxic effects of histone deacetylase inhibitor FK228 (depsipeptide, formally named FR901228) in combination with conventional anti-leukemia/lymphoma agents against human leukemia/lymphoma cell lines
-
Kano Y, Akutsu M, Tsunoda S, Izumi T, Kobayashi H, Mano H, Furukawa Y. Cytotoxic effects of histone deacetylase inhibitor FK228 (depsipeptide, formally named FR901228) in combination with conventional anti-leukemia/lymphoma agents against human leukemia/lymphoma cell lines. Invest New Drugs. 2007;25: 31-40.
-
(2007)
Invest New Drugs
, vol.25
, pp. 31-40
-
-
Kano, Y.1
Akutsu, M.2
Tsunoda, S.3
Izumi, T.4
Kobayashi, H.5
Mano, H.6
Furukawa, Y.7
-
21
-
-
33947126086
-
The use of histone deacetylase inhibitor FK228 and dna hypomethylation agent 5-azacytidine in human bladder cancer therapy
-
Karam JA, Fan J, Stanfield J, Richer E, Benaim EA, Frenkel E, Antich P, Sagalowsky AI, Mason RP, Hsieh JT. The use of histone deacetylase inhibitor FK228 and DNA hypomethylation agent 5-azacytidine in human bladder cancer therapy. Int J Cancer. 2007;120:1795-802.
-
(2007)
Int J Cancer
, vol.120
, pp. 1795-1802
-
-
Karam, J.A.1
Fan, J.2
Stanfield, J.3
Richer, E.4
Benaim, E.A.5
Frenkel, E.6
Antich, P.7
Sagalowsky, A.I.8
Mason, R.P.9
Hsieh, J.T.10
-
22
-
-
2042505684
-
Analysis of histone deacetylase inhibitor, depsipeptide (FR901228), effect on multiple myeloma
-
Khan SB, Maududi T, Barton K, Ayers J, Alkan S. Analysis of histone deacetylase inhibitor, depsipeptide (FR901228), effect on multiple myeloma. Br J Haematol. 2004;125:156-61.
-
(2004)
Br J Haematol
, vol.125
, pp. 156-161
-
-
Khan, S.B.1
Maududi, T.2
Barton, K.3
Ayers, J.4
Alkan, S.5
-
23
-
-
84858640254
-
Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma
-
Santo L, Hideshima T, Kung AL, Tseng JC, Tamang D, Yang M, Jarpe M, van Duzer JH, Mazitschek R, Ogier WC, Cirstea D, Rodig S, Eda H, Scullen T, Canavese M, Bradner J, Anderson KC, Jones SS, Raje N. Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. Blood. 2012;119:2579-89.
-
(2012)
Blood
, vol.119
, pp. 2579-2589
-
-
Santo, L.1
Hideshima, T.2
Kung, A.L.3
Tseng, J.C.4
Tamang, D.5
Yang, M.6
Jarpe, M.7
Van Duzer, J.H.8
Mazitschek, R.9
Ogier, W.C.10
Cirstea, D.11
Rodig, S.12
Eda, H.13
Scullen, T.14
Canavese, M.15
Bradner, J.16
Anderson, K.C.17
Jones, S.S.18
Raje, N.19
-
24
-
-
0346020435
-
The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress
-
Kawaguchi Y, Kovacs JJ, McLaurin A, Vance JM, Ito A, Yao TP. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell. 2003;115: 727-38.
-
(2003)
Cell
, vol.115
, pp. 727-738
-
-
Kawaguchi, Y.1
Kovacs, J.J.2
Mclaurin, A.3
Vance, J.M.4
Ito, A.5
Yao, T.P.6
-
25
-
-
0036303981
-
Hassles with taking out the garbage: Aggravating aggresomes
-
Garcia-Mata R, Gao YS, Sztul E. Hassles with taking out the garbage: Aggravating aggresomes. Traffic. 2002;3:388-96.
-
(2002)
Traffic
, vol.3
, pp. 388-396
-
-
Garcia-Mata, R.1
Gao, Y.S.2
Sztul, E.3
-
26
-
-
20844435806
-
Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma
-
Hideshima T, Bradner JE, Wong J, Chauhan D, Richardson P, Schreiber SL, Anderson KC. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci USA. 2005; 102:8567-72.
-
(2005)
Proc Natl Acad Sci USA
, vol.102
, pp. 8567-8572
-
-
Hideshima, T.1
Bradner, J.E.2
Wong, J.3
Chauhan, D.4
Richardson, P.5
Schreiber, S.L.6
Anderson, K.C.7
-
27
-
-
34548138147
-
A novel, mercaptoketone-based HDAC inhibitor, KD5170 exerts marked inhibition of osteoclast formation and anti-myeloma activity in vitro
-
Feng R, Hager JH, Hassig CA, Scranton SA, Payne JE, Mapara MY, Roodman D, Lentzsch S. A novel, mercaptoketone-based HDAC inhibitor, KD5170 exerts marked inhibition of osteoclast formation and anti-myeloma activity in vitro. Blood. 2006;108: 991a.
-
(2006)
Blood
, vol.108
-
-
Feng, R.1
Hager, J.H.2
Hassig, C.A.3
Scranton, S.A.4
Payne, J.E.5
Mapara, M.Y.6
Roodman, D.7
Lentzsch, S.8
-
28
-
-
3042785975
-
A review of depsipeptide and other histone deacetylase inhibitors in clinical trials
-
Piekarz R, Bates S. A review of depsipeptide and other histone deacetylase inhibitors in clinical trials. Curr Pharm Des. 2004;10: 2289-98.
-
(2004)
Curr Pharm des
, vol.10
, pp. 2289-2298
-
-
Piekarz, R.1
Bates, S.2
-
29
-
-
16344391638
-
In vitro study of CI-994, a histone deacetylase inhibitor, in non-small cell lung cancer cell lines
-
Loprevite M, Tiseo M, Grossi F, Scolaro T, Semino C, Pandolfi A, Favoni R, Ardizzoni A. In vitro study of CI-994, a histone deacetylase inhibitor, in non-small cell lung cancer cell lines. Oncol Res. 2005;15:39-48.
-
(2005)
Oncol Res
, vol.15
, pp. 39-48
-
-
Loprevite, M.1
Tiseo, M.2
Grossi, F.3
Scolaro, T.4
Semino, C.5
Pandolfi, A.6
Favoni, R.7
Ardizzoni, A.8
-
30
-
-
68949212379
-
Lysine acetylation targets protein complexes and co-regulates major cellular functions
-
Choudhary C, Kumar C, Gnad F, Nielsen ML, Rehman M, Walther TC, Olsen JV, Mann M. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science. 2009;325:834-40.
-
(2009)
Science
, vol.325
, pp. 834-840
-
-
Choudhary, C.1
Kumar, C.2
Gnad, F.3
Nielsen, M.L.4
Rehman, M.5
Walther, T.C.6
Olsen, J.V.7
Mann, M.8
-
31
-
-
0037589018
-
Molecular sequelae of histone deacetylase inhibition in human malignant B cells
-
Mitsiades N, Mitsiades CS, Richardson PG, McMullan C, Poulaki V, Fanourakis G, Schlossman R, Chauhan D, Munshi NC, Hideshima T, Richon VM, Marks PA, Anderson KC. Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood. 2003;101:4055-62.
-
(2003)
Blood
, vol.101
, pp. 4055-4062
-
-
Mitsiades, N.1
Mitsiades, C.S.2
Richardson, P.G.3
McMullan, C.4
Poulaki, V.5
Fanourakis, G.6
Schlossman, R.7
Chauhan, D.8
Munshi, N.C.9
Hideshima, T.10
Richon, V.M.11
Marks, P.A.12
Anderson, K.C.13
-
32
-
-
23244459828
-
Interactive effects of HDAC inhibitors and trail on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma
-
Fandy TE, Shankar S, Ross DD, Sausville E, Srivastava RK. Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma. Neoplasia. 2005;7:646-57.
-
(2005)
Neoplasia
, vol.7
, pp. 646-657
-
-
Fandy, T.E.1
Shankar, S.2
Ross, D.D.3
Sausville, E.4
Srivastava, R.K.5
-
33
-
-
84865305652
-
Suberoylanilide hydroxamic acid as a radiosensitizer through modulation of RAD51 protein and inhibition of homologydirected repair in multiple myeloma
-
Chen X, Wong P, Radany EH, Stark JM, Laulier C, Wong JY. Suberoylanilide hydroxamic acid as a radiosensitizer through modulation of RAD51 protein and inhibition of homologydirected repair in multiple myeloma. Mol Cancer Res. 2012;10: 1052-64.
-
(2012)
Mol Cancer Res
, vol.10
, pp. 1052-1064
-
-
Chen, X.1
Wong, P.2
Radany, E.H.3
Stark, J.M.4
Laulier, C.5
Wong, J.Y.6
-
34
-
-
77955871803
-
Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma
-
Kikuchi J, Wada T, Shimizu R, Izumi T, Akutsu M, Mitsunaga K, Noborio-Hatano K, Nobuyoshi M, Ozawa K, Kano Y, Furukawa Y. Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma. Blood. 2010;116:406-17.
-
(2010)
Blood
, vol.116
, pp. 406-417
-
-
Kikuchi, J.1
Wada, T.2
Shimizu, R.3
Izumi, T.4
Akutsu, M.5
Mitsunaga, K.6
Noborio-Hatano, K.7
Nobuyoshi, M.8
Ozawa, K.9
Kano, Y.10
Furukawa, Y.11
-
35
-
-
38849130851
-
Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice
-
Mukherjee S, Raje N, Schoonmaker JA, Liu JC, Hideshima T, Wein MN, Jones DC, Vallet S, Bouxsein ML, Pozzi S, Chhetri S, Seo YD, Aronson JP, Patel C, Fulciniti M, Purton LE, Glimcher LH, Lian JB, Stein G, Anderson KC, Scadden DT. Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice. J Clin Invest. 2008;118:491-504.
-
(2008)
J Clin Invest
, vol.118
, pp. 491-504
-
-
Mukherjee, S.1
Raje, N.2
Schoonmaker, J.A.3
Liu, J.C.4
Hideshima, T.5
Wein, M.N.6
Jones, D.C.7
Vallet, S.8
Bouxsein, M.L.9
Pozzi, S.10
Chhetri, S.11
Seo, Y.D.12
Aronson, J.P.13
Patel, C.14
Fulciniti, M.15
Purton, L.E.16
Glimcher, L.H.17
Lian, J.B.18
Stein, G.19
Anderson, K.C.20
Scadden, D.T.21
more..
-
36
-
-
67650456888
-
Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: Effect on myeloma bone disease in the 5T2MM murine model of myeloma
-
Deleu S, Lemaire M, Arts J, Menu E, Van Valckenborgh E, Van de Broek I, De Raeve H, Coulton L, Van Camp B, Croucher P, Van der kerken K. Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: effect on myeloma bone disease in the 5T2MM murine model of myeloma. Cancer Res. 2009;69:5307-11.
-
(2009)
Cancer Res
, vol.69
, pp. 5307-5311
-
-
De Leu, S.1
Lemaire, M.2
Arts, J.3
Menu, E.4
Van Valckenborgh, E.5
Van De Broek, I.6
De Raeve, H.7
Coulton, L.8
Van Camp, B.9
Croucher, P.10
Van Der Kerken, K.11
-
37
-
-
12444321545
-
Phase I clinical trial of histone deacetylase inhibitor: Suberoylanilide hydroxamic acid administered intravenously
-
Kelly WK, Richon VM, O'Connor O, Curley T, MacGregor- Curtelli B, Tong W, Klang M, Schwartz L, Richardson S, Rosa E, Drobnjak M, Cordon-Cordo C, Chiao JH, Rifkind R, Marks PA, Scher H. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res. 2003;9:3578-88.
-
(2003)
Clin Cancer Res
, vol.9
, pp. 3578-3588
-
-
Kelly, W.K.1
Richon, V.M.2
O'Connor, O.3
Curley, T.4
MacGregor-Curtelli, B.5
Tong, W.6
Klang, M.7
Schwartz, L.8
Richardson, S.9
Rosa, E.10
Drobnjak, M.11
Cordon-Cordo, C.12
Chiao, J.H.13
Rifkind, R.14
Marks, P.A.15
Scher, H.16
-
38
-
-
21244464349
-
Phase i study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer
-
Kelly WK, O'Connor OA, Krug LM, Chiao JH, Heaney M, Curley T, MacGregore-Cortelli B, Tong W, Secrist JP, Schwartz L, Richardson S, Chu E, Olgac S, Marks PA, Scher H, Richon VM. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol. 2005;23:3923-31.
-
(2005)
J Clin Oncol
, vol.23
, pp. 3923-3931
-
-
Kelly, W.K.1
O'Connor, O.A.2
Krug, L.M.3
Chiao, J.H.4
Heaney, M.5
Curley, T.6
Macgregore-Cortelli, B.7
Tong, W.8
Secrist, J.P.9
Schwartz, L.10
Richardson, S.11
Chu, E.12
Olgac, S.13
Marks, P.A.14
Scher, H.15
Richon, V.M.16
-
39
-
-
33244458274
-
Potential role of histone deacetylase inhibitors in mesothelioma: Clinical experience with suberoylanilide hydroxamic acid
-
Krug LM, Curley T, Schwartz L, Richardson S, Marks P, Chiao J, Kelly WK. Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid. Clin Lung Cancer. 2006;7:257-61.
-
(2006)
Clin Lung Cancer
, vol.7
, pp. 257-261
-
-
Krug, L.M.1
Curley, T.2
Schwartz, L.3
Richardson, S.4
Marks, P.5
Chiao, J.6
Kelly, W.K.7
-
40
-
-
33845996135
-
Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous t-cell lymphoma (CTCL)
-
Duvic M, Talpur R, Ni X, Zhang C, Hazarika P, Kelly C, Chiao JH, Reilly JF, Ricker JL, Richon VM, Frankel SR. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood. 2007; 109:31-9.
-
(2007)
Blood
, vol.109
, pp. 31-39
-
-
Duvic, M.1
Talpur, R.2
Ni, X.3
Zhang, C.4
Hazarika, P.5
Kelly, C.6
Chiao, J.H.7
Reilly, J.F.8
Ricker, J.L.9
Richon, V.M.10
Frankel, S.R.11
-
41
-
-
39749103428
-
Phase i trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma
-
Richardson P, Mitsiades C, Colson K, Reilly E, McBride L, Chiao J, Sun L, Ricker J, Rizvi S, Oerth C, Atkins B, Fearen I, Anderson K, Siegel D. Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Leuk Lymphoma. 2008;49:502-7.
-
(2008)
Leuk Lymphoma
, vol.49
, pp. 502-507
-
-
Richardson, P.1
Mitsiades, C.2
Colson, K.3
Reilly, E.4
Mcbride, L.5
Chiao, J.6
Sun, L.7
Ricker, J.8
Rizvi, S.9
Oerth, C.10
Atkins, B.11
Fearen, I.12
Anderson, K.13
Siegel, D.14
-
42
-
-
0036301281
-
Phase i trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms
-
Sandor V, Bakke S, Robey RW, Kang MH, Blagosklonny MV, Bender J, Brooks R, Piekarz RL, Tucker E, Figg WD, Chan KK, Goldspiel B, Fojo AT, Balcerzak SP, Bates SE. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res. 2002;8:718-28.
-
(2002)
Clin Cancer Res
, vol.8
, pp. 718-728
-
-
Sandor, V.1
Bakke, S.2
Robey, R.W.3
Kang, M.H.4
Blagosklonny, M.V.5
Bender, J.6
Brooks, R.7
Piekarz, R.L.8
Tucker, E.9
Figg, W.D.10
Chan, K.K.11
Goldspiel, B.12
Fojo, A.T.13
Balcerzak, S.P.14
Bates, S.E.15
-
43
-
-
18644379905
-
A phase i trial of depsipeptide (FR901228) in patients with advanced cancer
-
Marshall JL, Rizvi N, Kauh J, Dahut W, Figuera M, Kang MH, Figg WD, Wainer I, Chaissang C, Li MZ, Hawkins MJ. A phase I trial of depsipeptide (FR901228) in patients with advanced cancer. J Exp Ther Oncol. 2002;2:325-32.
-
(2002)
J Exp Ther Oncol
, vol.2
, pp. 325-332
-
-
Marshall, J.L.1
Rizvi, N.2
Kauh, J.3
Dahut, W.4
Figuera, M.5
Kang, M.H.6
Figg, W.D.7
Wainer, I.8
Chaissang, C.9
Li, M.Z.10
Hawkins, M.J.11
-
44
-
-
19944432566
-
A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia
-
Byrd JC, Marcucci G, Parthun MR, Xiao JJ, Klisovic RB, Moran M, Lin TS, Liu S, Sklenar AR, Davis ME, Lucas DM, Fischer B, Shank R, Tejaswi SL, Binkley P, Wright J, Chan KK, Grever MR. A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood. 2005;105:959-67.
-
(2005)
Blood
, vol.105
, pp. 959-967
-
-
Byrd, J.C.1
Marcucci, G.2
Parthun, M.R.3
Xiao, J.J.4
Klisovic, R.B.5
Moran, M.6
Lin, T.S.7
Liu, S.8
Sklenar, A.R.9
Davis, M.E.10
Lucas, D.M.11
Fischer, B.12
Shank, R.13
Tejaswi, S.L.14
Binkley, P.15
Wright, J.16
Chan, K.K.17
Grever, M.R.18
-
45
-
-
33645069138
-
Increased MDR1 expression in normal and malignant peripheral blood mononuclear cells obtained from patients receiving depsipeptide (FR901228, FK228, NSC630176)
-
Robey RW, Zhan Z, Piekarz RL, Kayastha GL, Fojo T, Bates SE. Increased MDR1 expression in normal and malignant peripheral blood mononuclear cells obtained from patients receiving depsipeptide (FR901228, FK228, NSC630176). Clin Cancer Res. 2006;12:1547-55.
-
(2006)
Clin Cancer Res
, vol.12
, pp. 1547-1555
-
-
Robey, R.W.1
Zhan, Z.2
Piekarz, R.L.3
Kayastha, G.L.4
Fojo, T.5
Bates, S.E.6
-
46
-
-
33749049594
-
A phase II study of depsipeptide in refractory metastatic renal cell cancer
-
Stadler WM, Margolin K, Ferber S, McCulloch W, Thompson JA. A phase II study of depsipeptide in refractory metastatic renal cell cancer. Clin Genitourin Cancer. 2006;5:57-60.
-
(2006)
Clin Genitourin Cancer
, vol.5
, pp. 57-60
-
-
Stadler, W.M.1
Margolin, K.2
Ferber, S.3
McCulloch, W.4
Thompson, J.A.5
-
47
-
-
78650992102
-
Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma
-
Niesvizky R, Ely S, Mark T, Aggarwal S, Gabrilove JL, Wright JJ, Chen-Kiang S, Sparano JA. Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma. Cancer. 2011;117:336-42.
-
(2011)
Cancer
, vol.117
, pp. 336-342
-
-
Niesvizky, R.1
Ely, S.2
Mark, T.3
Aggarwal, S.4
Gabrilove, J.L.5
Wright, J.J.6
Chen-Kiang, S.7
Sparano, J.A.8
-
48
-
-
77951708371
-
CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity
-
Lai CJ, Bao R, Tao X, Wang J, Atoyan R, Qu H, Wang DG, Yin L, Samson M, Forrester J, Zifcak B, Xu GX, DellaRocca S, Zhai HX, Cai X, Munger WE, Keegan M, Pepicelli CV, Qian C. CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity. Cancer Res. 2010;70:3647-56.
-
(2010)
Cancer Res
, vol.70
, pp. 3647-3656
-
-
Lai, C.J.1
Bao, R.2
Tao, X.3
Wang, J.4
Atoyan, R.5
Qu, H.6
Wang, D.G.7
Yin, L.8
Samson, M.9
Forrester, J.10
Zifcak, B.11
Xu, G.X.12
Dellarocca, S.13
Zhai, H.X.14
Cai, X.15
Munger, W.E.16
Keegan, M.17
Pepicelli, C.V.18
Qian, C.19
|